Proportion of the Treatment Effect Explained by Log10 Hemagglutination Inhibition Titer as the Correlate of Protection Using the Freedman Method
| Influenza Illness Endpoint . | Proportion of Vaccination Effect . | . | . | . | . |
|---|---|---|---|---|---|
| . | Observed From Clinical Trial . | Estimated From Resampling (Bootstrap) Method . | . | . | . |
| . | . | Mean . | Median . | 2.5th Percentile . | 97.5th Percentile . |
| RT-PCR–confirmed influenza illness: A/H1N1 | 0.750 | 0.792 | 0.755 | 0.367 | 1.479 |
| RT-PCR–confirmed influenza illness: A/H3N2 | 1.461 | 1.503 | 1.462 | 1.020 | 2.180 |
| Influenza Illness Endpoint . | Proportion of Vaccination Effect . | . | . | . | . |
|---|---|---|---|---|---|
| . | Observed From Clinical Trial . | Estimated From Resampling (Bootstrap) Method . | . | . | . |
| . | . | Mean . | Median . | 2.5th Percentile . | 97.5th Percentile . |
| RT-PCR–confirmed influenza illness: A/H1N1 | 0.750 | 0.792 | 0.755 | 0.367 | 1.479 |
| RT-PCR–confirmed influenza illness: A/H3N2 | 1.461 | 1.503 | 1.462 | 1.020 | 2.180 |
Per-protocol correlate of protection. Hemagglutination inhibition titer was measured at 28 days after last vaccination. Mean, median, 2.5th percentile, and 97.5th percentile of the proportion of the treatment effect were calculated using the bootstrap method with unrestricted random sampling. The parameter calculated can be >100% using this technique, but in this case, it is considered to be 100%.
Abbreviation: RT-PCR, reverse-transcription polymerase chain reaction.
Proportion of the Treatment Effect Explained by Log10 Hemagglutination Inhibition Titer as the Correlate of Protection Using the Freedman Method
| Influenza Illness Endpoint . | Proportion of Vaccination Effect . | . | . | . | . |
|---|---|---|---|---|---|
| . | Observed From Clinical Trial . | Estimated From Resampling (Bootstrap) Method . | . | . | . |
| . | . | Mean . | Median . | 2.5th Percentile . | 97.5th Percentile . |
| RT-PCR–confirmed influenza illness: A/H1N1 | 0.750 | 0.792 | 0.755 | 0.367 | 1.479 |
| RT-PCR–confirmed influenza illness: A/H3N2 | 1.461 | 1.503 | 1.462 | 1.020 | 2.180 |
| Influenza Illness Endpoint . | Proportion of Vaccination Effect . | . | . | . | . |
|---|---|---|---|---|---|
| . | Observed From Clinical Trial . | Estimated From Resampling (Bootstrap) Method . | . | . | . |
| . | . | Mean . | Median . | 2.5th Percentile . | 97.5th Percentile . |
| RT-PCR–confirmed influenza illness: A/H1N1 | 0.750 | 0.792 | 0.755 | 0.367 | 1.479 |
| RT-PCR–confirmed influenza illness: A/H3N2 | 1.461 | 1.503 | 1.462 | 1.020 | 2.180 |
Per-protocol correlate of protection. Hemagglutination inhibition titer was measured at 28 days after last vaccination. Mean, median, 2.5th percentile, and 97.5th percentile of the proportion of the treatment effect were calculated using the bootstrap method with unrestricted random sampling. The parameter calculated can be >100% using this technique, but in this case, it is considered to be 100%.
Abbreviation: RT-PCR, reverse-transcription polymerase chain reaction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
